Key result
Ivabradine use in chronic heart failure is outlined, providing guidance on pharmacodynamics, pharmacokinetics, initiation, monitoring, eligibility criteria, and contraindications.
This article serves as a practical guide for clinicians on the appropriate use, initiation, and monitoring of ivabradine in chronic heart failure management.
Guides ivabradine initiation and monitoring in chronic HF; leaves open need for updated real-world validation.
This drug-focused article looks at the pharmacodynamics and pharmacokinetics of ivabradine and outlines its use in chronic heart failure. It puts the use of ivabradine into the context of other pharmacological management and gives guidance on initiation and monitoring, as well as what clinical factors need to be taken into account to ensure safe management of patients prescribed this medication. This includes the information that needs to be shared with the patient, the criteria for eligibility, and contraindications for this treatment.
No takes yet. Share an insight, caveat, or question.
Hannah Waterhouse (2015) conducted a review in chronic heart failure. ivabradine was evaluated. Ivabradine use in chronic heart failure is outlined, providing guidance on pharmacodynamics, pharmacokinetics, initiation, monitoring, eligibility criteria, and contraindications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: